MRI strain analysis as a novel modality for the assessment of myocardial function following stem cell therapy-results from Amorcyte trial

Bhatti, Sabha; Hakeem, Abdul; Taylor, Michael D.; Chung, Eugene S.; Quyyumi, Arshed A.; Oshinski, John N.; Pecora, Andrew L.; Kereiakes, Dean J.; Hor, Kan; Mazur, Wojciech

doi:10.1186/1532-429x-13-s1-p86

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concept of myocardial strain was extended from echocardiography also to MRI detecting subtle improvements in myocardial function earlier than commonly used methods for myocardial function assessment. Myocardial MRI strain imaging has been evaluated only in one study, but when assessed showed significant increment in circumferential strain in the myocardial segments adjacent to the infarction area[ 22 ].…”

Section: Structural End-pointsmentioning

confidence: 99%

Pursuing meaningful end-points for stem cell therapy assessment in ischemic cardiac disease

Dorobanţu¹,

Popa-Fotea²,

Popa³

et al. 2017

WJSC

View full text Add to dashboard Cite

Despite optimal interventional and medical therapy, ischemic heart disease is still an important cause of morbidity and mortality worldwide. Although not included in standard of care rehabilitation, stem cell therapy (SCT) could be a solution for prompting cardiac regeneration. Multiple studies have been published from the beginning of SCT until now, but overall no unanimous conclusion could be drawn in part due to the lack of appropriate end-points. In order to appreciate the impact of SCT, multiple markers from different categories should be considered: Structural, biological, functional, physiological, but also major adverse cardiac events or quality of life. Imaging end-points are among the most used - especially left ventricle ejection fraction (LVEF) measured through different methods. Other imaging parameters are infarct size, myocardial viability and perfusion. The impact of SCT on all of the aforementioned end-points is controversial and debatable. 2D-echocardiography is widely exploited, but new approaches such as tissue Doppler, strain/strain rate or 3D-echocardiography are more accurate, especially since the latter one is comparable with the MRI gold standard estimation of LVEF. Apart from the objective parameters, there are also patient-centered evaluations to reveal the benefits of SCT, such as quality of life and performance status, the most valuable from the patient point of view. Emerging parameters investigating molecular pathways such as non-coding RNAs or inflammation cytokines have a high potential as prognostic factors. Due to the disadvantages of current techniques, new imaging methods with labelled cells tracked along their lifetime seem promising, but until now only pre-clinical trials have been conducted in humans. Overall, SCT is characterized by high heterogeneity not only in preparation, administration and type of cells, but also in quantification of therapy effects.

show abstract

Section: Structural End-pointsmentioning

confidence: 99%